Daria Afenteva
@afenteva.bsky.social
🎓 PhD student in Biomedicine
📍 University of Helsinki, Finland
🧬 Ovarian cancer researcher
🏃♀️ Skier and runner
📍 University of Helsinki, Finland
🧬 Ovarian cancer researcher
🏃♀️ Skier and runner
Pikku Joulu in the lab 🎄
December 17, 2025 at 2:13 PM
Pikku Joulu in the lab 🎄
Reposted by Daria Afenteva
Applications for the 2026 Leena Peltonen School of Human Genetics are open!📢
The school brings together ~20 global leaders and ~20 advanced PhD students for an intensive, discussion-driven week shaping the future of genomics.
📅 July 26–30
📍 Wellcome Genome Campus, UK
📝 Apply by March 6: lpshg.com
The school brings together ~20 global leaders and ~20 advanced PhD students for an intensive, discussion-driven week shaping the future of genomics.
📅 July 26–30
📍 Wellcome Genome Campus, UK
📝 Apply by March 6: lpshg.com
December 16, 2025 at 8:10 AM
Applications for the 2026 Leena Peltonen School of Human Genetics are open!📢
The school brings together ~20 global leaders and ~20 advanced PhD students for an intensive, discussion-driven week shaping the future of genomics.
📅 July 26–30
📍 Wellcome Genome Campus, UK
📝 Apply by March 6: lpshg.com
The school brings together ~20 global leaders and ~20 advanced PhD students for an intensive, discussion-driven week shaping the future of genomics.
📅 July 26–30
📍 Wellcome Genome Campus, UK
📝 Apply by March 6: lpshg.com
Had a great time at the DYNAMITE 🧨 meeting in Copenhagen this week. Huge thanks to Tuula Kallunki and the whole team for hosting us so warmly!
#DYNAMITE #ovariancancer #research
#DYNAMITE #ovariancancer #research
December 10, 2025 at 5:08 PM
Had a great time at the DYNAMITE 🧨 meeting in Copenhagen this week. Huge thanks to Tuula Kallunki and the whole team for hosting us so warmly!
#DYNAMITE #ovariancancer #research
#DYNAMITE #ovariancancer #research
I am grateful to @syopasaatio.bsky.social for awarding ma a dissertation grant 🌸
Huge congrats also to @anna-vaharautio.bsky.social!!!
Huge congrats also to @anna-vaharautio.bsky.social!!!
Syöpäsäätiön vuosittain saamilla lahjoitusvaroilla tuetaan monipuolisesti syövän tutkimushankkeita - kiitos lahjoittajien ❤️ Nyt jaamme jälleen syöpätutkimukseen ennätysmäärän apurahoja, yhteensä 8 miljoonaa euroa. Lue lisää täältä: syopasaatio.fi/syopasaatio-... #syöpätutkimus #apurahat #tiede
Syöpäsäätiö tukee apurahoin suomalaista syöpätutkimusta 8 miljoonalla eurolla - Syöpäsäätiö
Syöpäsäätiö jakaa jälleen syöpätutkimukseen ennätysmäärän apurahoja, yhteensä 8 miljoonaa euroa. Dosentti Anna Vähärautiolle myönnettin suurapuraha.
syopasaatio.fi
November 20, 2025 at 12:25 PM
I am grateful to @syopasaatio.bsky.social for awarding ma a dissertation grant 🌸
Huge congrats also to @anna-vaharautio.bsky.social!!!
Huge congrats also to @anna-vaharautio.bsky.social!!!
🎉 Huge congrats to Oskari on the acceptance of his final PhD paper! He built Histolytics - a Python package for spatial analysis of whole-slide images 🌠🔬
Try it: github.com/HautaniemiLa...
Try it: github.com/HautaniemiLa...
November 12, 2025 at 4:00 PM
🎉 Huge congrats to Oskari on the acceptance of his final PhD paper! He built Histolytics - a Python package for spatial analysis of whole-slide images 🌠🔬
Try it: github.com/HautaniemiLa...
Try it: github.com/HautaniemiLa...
Reposted by Daria Afenteva
Are you using any of our factor models, such as MOFA? 🛵
You might’ve found it challenging to tailor them to your specific use cases - not anymore!
Introducing MOFA-FLEX: a flexible, modular factor analysis framework designed for customizable modeling across diverse multi-omics data scenarios. 1/n
You might’ve found it challenging to tailor them to your specific use cases - not anymore!
Introducing MOFA-FLEX: a flexible, modular factor analysis framework designed for customizable modeling across diverse multi-omics data scenarios. 1/n
November 7, 2025 at 10:29 AM
Are you using any of our factor models, such as MOFA? 🛵
You might’ve found it challenging to tailor them to your specific use cases - not anymore!
Introducing MOFA-FLEX: a flexible, modular factor analysis framework designed for customizable modeling across diverse multi-omics data scenarios. 1/n
You might’ve found it challenging to tailor them to your specific use cases - not anymore!
Introducing MOFA-FLEX: a flexible, modular factor analysis framework designed for customizable modeling across diverse multi-omics data scenarios. 1/n
Reposted by Daria Afenteva
🥁 Check out our new preprint on OmniPath, the prior knowledge resource for #SystemsBiology, and its brand-new OmniPath Explorer web app! 🥳
📖 Preprint: www.biorxiv.org/content/10.1...
🔍 Explorer: explore.omnipathdb.org
OmniPath integrates 160+ resources for multi-omics analysis & modeling.
🧶⬇️
📖 Preprint: www.biorxiv.org/content/10.1...
🔍 Explorer: explore.omnipathdb.org
OmniPath integrates 160+ resources for multi-omics analysis & modeling.
🧶⬇️
September 17, 2025 at 1:10 PM
🥁 Check out our new preprint on OmniPath, the prior knowledge resource for #SystemsBiology, and its brand-new OmniPath Explorer web app! 🥳
📖 Preprint: www.biorxiv.org/content/10.1...
🔍 Explorer: explore.omnipathdb.org
OmniPath integrates 160+ resources for multi-omics analysis & modeling.
🧶⬇️
📖 Preprint: www.biorxiv.org/content/10.1...
🔍 Explorer: explore.omnipathdb.org
OmniPath integrates 160+ resources for multi-omics analysis & modeling.
🧶⬇️
Reposted by Daria Afenteva
Online now: Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
Afenteva et al. combine multi-omics, single-cell, and functional analyses to show that diminished type I interferon signaling in cancer cells underlies inherent platinum resistance in ovarian high-grade serous carcinoma. Exogenous interferon-alpha sensitizes cancer cells to cisplatin, nominating interferon pathway stimulation as a precision strategy for refractory disease.
dlvr.it
September 1, 2025 at 12:27 PM
Online now: Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
🎉 After almost 3y in making, my first first-author PhD paper is out in Cell Reports Medicine!
🔗 Link: www.cell.com/cell-reports...
🧵 1/3
🔗 Link: www.cell.com/cell-reports...
🧵 1/3
Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer
Afenteva et al. combine multi-omics, single-cell, and functional analyses to show
that diminished type I interferon signaling in cancer cells underlies inherent platinum
resistance in ovarian high-gra...
www.cell.com
August 31, 2025 at 9:45 PM
🎉 After almost 3y in making, my first first-author PhD paper is out in Cell Reports Medicine!
🔗 Link: www.cell.com/cell-reports...
🧵 1/3
🔗 Link: www.cell.com/cell-reports...
🧵 1/3
Reposted by Daria Afenteva
Our Systema framework for evaluating genetic perturbation response prediction methods is now out in @natbiotech.nature.com ✨
Systema helps to evaluate perturbation response prediction methods by focusing on perturbation-specific effects rather than systematic variation 🎯
Systema helps to evaluate perturbation response prediction methods by focusing on perturbation-specific effects rather than systematic variation 🎯
Systema: a framework for evaluating genetic perturbation response prediction beyond systematic variation - @mariabrbic.bsky.social @mornitzan.bsky.social go.nature.com/4791kda
Systema: a framework for evaluating genetic perturbation response prediction beyond systematic variation - Nature Biotechnology
An evaluation framework isolates perturbation-specific effects in perturbation datasets.
go.nature.com
August 25, 2025 at 6:36 PM
Our Systema framework for evaluating genetic perturbation response prediction methods is now out in @natbiotech.nature.com ✨
Systema helps to evaluate perturbation response prediction methods by focusing on perturbation-specific effects rather than systematic variation 🎯
Systema helps to evaluate perturbation response prediction methods by focusing on perturbation-specific effects rather than systematic variation 🎯
August 5, 2025 at 1:57 PM
Reposted by Daria Afenteva
Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis https://www.biorxiv.org/content/10.1101/2025.07.28.667199v1
July 31, 2025 at 4:49 PM
Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis https://www.biorxiv.org/content/10.1101/2025.07.28.667199v1
Reposted by Daria Afenteva
🎉 The revised version of CORNETO, our unified Python framework for knowledge-driven network inference from omics data, is published in peer reviewed form
🔗 Paper: www.nature.com/articles/s42...
📖 News & Views: www.nature.com/articles/s42...
💻 Code: corneto.org
🧵 Thread 👇
🔗 Paper: www.nature.com/articles/s42...
📖 News & Views: www.nature.com/articles/s42...
💻 Code: corneto.org
🧵 Thread 👇
July 22, 2025 at 3:23 PM
🎉 The revised version of CORNETO, our unified Python framework for knowledge-driven network inference from omics data, is published in peer reviewed form
🔗 Paper: www.nature.com/articles/s42...
📖 News & Views: www.nature.com/articles/s42...
💻 Code: corneto.org
🧵 Thread 👇
🔗 Paper: www.nature.com/articles/s42...
📖 News & Views: www.nature.com/articles/s42...
💻 Code: corneto.org
🧵 Thread 👇
Reposted by Daria Afenteva
Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy https://www.biorxiv.org/content/10.1101/2025.06.24.661404v1
June 25, 2025 at 3:48 PM
Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy https://www.biorxiv.org/content/10.1101/2025.06.24.661404v1
Reposted by Daria Afenteva
📢ONLINE @naturegenet.bsky.social
📰Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring.
By Wenbao Yu, Kai Tan and colleagues.
⬇️
www.nature.com/articles/s41...
📰Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring.
By Wenbao Yu, Kai Tan and colleagues.
⬇️
www.nature.com/articles/s41...
Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring - Nature Genetics
Analysis of pre- and post-chemotherapy samples collected from 22 patients with high-risk neuroblastoma using single-nucleus RNA and ATAC sequencing and spatial omics characterizes therapy-related chan...
www.nature.com
April 23, 2025 at 4:03 PM
📢ONLINE @naturegenet.bsky.social
📰Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring.
By Wenbao Yu, Kai Tan and colleagues.
⬇️
www.nature.com/articles/s41...
📰Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring.
By Wenbao Yu, Kai Tan and colleagues.
⬇️
www.nature.com/articles/s41...
Reposted by Daria Afenteva
📢ONLINE @natgenet.nature.com
📰Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.
By Avishay Spitzer, Mario L. Suvà and colleagues.
⬇️
www.nature.com/articles/s41...
📰Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.
By Avishay Spitzer, Mario L. Suvà and colleagues.
⬇️
www.nature.com/articles/s41...
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics - Nature Genetics
Comparison of paired primary and recurrent glioblastomas at the single-cell transcriptomic level describes molecular and cellular trajectories associated with tumor recurrence, highlighting extensive ...
www.nature.com
May 13, 2025 at 12:05 PM
📢ONLINE @natgenet.nature.com
📰Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.
By Avishay Spitzer, Mario L. Suvà and colleagues.
⬇️
www.nature.com/articles/s41...
📰Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.
By Avishay Spitzer, Mario L. Suvà and colleagues.
⬇️
www.nature.com/articles/s41...
Reposted by Daria Afenteva
📢OUT TODAY @natgenet.nature.com
📰Predicting resistance to chemotherapy using chromosomal instability signatures.
By @jsneaththompson.bsky.social, @gmaci.bsky.social and colleagues.
⬇️
www.nature.com/articles/s41...
📰Predicting resistance to chemotherapy using chromosomal instability signatures.
By @jsneaththompson.bsky.social, @gmaci.bsky.social and colleagues.
⬇️
www.nature.com/articles/s41...
June 23, 2025 at 2:18 PM
📢OUT TODAY @natgenet.nature.com
📰Predicting resistance to chemotherapy using chromosomal instability signatures.
By @jsneaththompson.bsky.social, @gmaci.bsky.social and colleagues.
⬇️
www.nature.com/articles/s41...
📰Predicting resistance to chemotherapy using chromosomal instability signatures.
By @jsneaththompson.bsky.social, @gmaci.bsky.social and colleagues.
⬇️
www.nature.com/articles/s41...
Reposted by Daria Afenteva
Epigenetic Subtypes of High-Grade T1 Bladder Cancer Reveal Intra-Tumor Heterogeneity and Distinct Interactions with Tumor Microenvironment. https://www.biorxiv.org/content/10.1101/2025.06.20.659124v1
June 21, 2025 at 1:46 AM
Epigenetic Subtypes of High-Grade T1 Bladder Cancer Reveal Intra-Tumor Heterogeneity and Distinct Interactions with Tumor Microenvironment. https://www.biorxiv.org/content/10.1101/2025.06.20.659124v1
Reposted by Daria Afenteva
Online now: Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
Yates and Mathey-Andrews et al. dissect the cellular and spatial heterogeneity of esophageal adenocarcinoma across clinical stages. They identify five malignant cell programs with distinct transcriptomic and epigenetic profiles, linked to disease progression, prognosis, and immune response. These programs interact with the tumor microenvironment, highlighting potential therapeutic targets.
dlvr.it
June 20, 2025 at 7:19 PM
Online now: Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
Glad to have presented our work on the longitudinal dynamics of transcriptome and chromatin accessibility in HGSC at the #EACR2025 in Lisbon 🇵🇹
June 17, 2025 at 9:03 PM
Glad to have presented our work on the longitudinal dynamics of transcriptome and chromatin accessibility in HGSC at the #EACR2025 in Lisbon 🇵🇹
Glad to share that the Ida Montinin Fund has awarded me a personal grant to support my doctoral studies at the @helsinki.fi 🤍
Learn about Ida Montini’s legacy (in Finnish): idamontininsaatio.fi
Thanks to my supervisor, Sampsa Hautaniemi, and colleagues for their support! 🙌
Learn about Ida Montini’s legacy (in Finnish): idamontininsaatio.fi
Thanks to my supervisor, Sampsa Hautaniemi, and colleagues for their support! 🙌
Ida Montinin Säätiö
idamontininsaatio.fi
June 10, 2025 at 3:33 PM
Glad to share that the Ida Montinin Fund has awarded me a personal grant to support my doctoral studies at the @helsinki.fi 🤍
Learn about Ida Montini’s legacy (in Finnish): idamontininsaatio.fi
Thanks to my supervisor, Sampsa Hautaniemi, and colleagues for their support! 🙌
Learn about Ida Montini’s legacy (in Finnish): idamontininsaatio.fi
Thanks to my supervisor, Sampsa Hautaniemi, and colleagues for their support! 🙌
Reposted by Daria Afenteva
Online now: Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype Online now:
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype
Seo et al. demonstrate that CXCL9+ macrophages interacting with CD8+ T cells improve survival outcome in patients with residual TNBC after neoadjuvant chemotherapy, while SPP1+ macrophages and basal-like features combined with HRD predict worse survival in HR+HER2− BCs, and ERBB2 structural variants predict worse survival outcomes in HER2+ BCs.
dlvr.it
June 7, 2025 at 12:27 PM
Online now: Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype Online now:
Reposted by Daria Afenteva
Improving Differential Expression and Survival Analyses with Sample Specific Compartment Deconvolution. https://www.biorxiv.org/content/10.1101/2025.06.04.657908v1
June 7, 2025 at 2:50 PM
Improving Differential Expression and Survival Analyses with Sample Specific Compartment Deconvolution. https://www.biorxiv.org/content/10.1101/2025.06.04.657908v1